You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Quantitative detection of methylation of FHIT and BRCA1 promoters in the serum of ductal breast cancer patients

Issue title: Frontiers in Biomedical Engineering and Biotechnology – Proceedings of the 4th International Conference on Biomedical Engineering and Biotechnology, 18–21 August 2015, Shanghai, China

Guest editors: Feng Liu, Dong-Hoon Lee, Ricardo Lagoa and Sandeep Kumar

Article type: Research Article

Authors: Liu, Limeia | Sun, Liyuana | Li, Chunheb | Li, Xinyanga | Zhang, Yuhongc | Yu, Yuna | Xia, Weia; *

Affiliations: [a] College of Medical Laboratory Science, Beihua University, Jilin, Jilin, China | [b] Jilin Central Hostpital, Jilin, Jilin, China | [c] Panshi Hostpital, Jilin, Jilin, China

Correspondence: [*] Address for correspondence: Wei Xia, College of Medical Laboratory Science, Beihua University, Jilin, Jilin, China. Tel.: 1864499799; Fax: 86-432-6460-8115; E-mail: [email protected].

Keywords: FHIT, BRCA1, methylation, breast cancer, cfDNA

DOI: 10.3233/BME-151527

Journal: Bio-Medical Materials and Engineering, vol. 26, no. s1, pp. S2217-S2222, 2015

Published: 2015
Get PDF open access

The development of carcinoma has been found to be associated with epigenetic modifications. The aim of this study was to estimate the methylation levels of FHIT and BRCA1 promoters using the bisulphite sequencing method (BSP) and high-resolution melting curve analysis (HRM) in the serum of patients with ductal breast carcinoma as a biomarker for the possible application of early diagnosis of breast cancer. The results showed that the methylation levels of both BRCA1 and FHIT promoters were higher in the serum of the breast ductal carcinoma group (BDC group) than those of the breast fibroadenoma group (BFA group), and the healthy individuals group (HI group). However, the methylation levels of the BRCA1 promoters were very low in all three groups compared to the levels of FHIT. The advanced quantitative detection of the samples with HRM showed that the FHIT promoter methylation level of the cfDNA in each serum was also very high in the BDC group compared to the HI group. The methylation level of FHIT was found to be significantly associated with breast cancer (p < 0.05). In conclusion, the methylation quantitative detection of FHIT promoter in serum may be useful for the early diagnosis of ductal breast carcinoma.

Show more